Startup profile for AstraNu: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

AstraNu funding, valuation and investors

Nokia Bell Labs photonics spinout building a compact swept-source optical coherence tomography imaging module for medical-device manufacturers.

Verified company research · funding, investors and latest developments

Keep track of AstraNu

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Seed

$3.5M · November 17, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$3.5M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

seed · Murray Hill, New Jersey, USA

Investors in latest funding

Lead: Celesta Capital

Other: New Jersey Innovation Evergreen Fund

Sources: latest funding · prnewswire.com Last verified: 2026-11-18

Overview

AstraNu, spun out from Nokia Bell Labs in May 2025, manufactures a swept-source optical coherence tomography (SS-OCT) imaging engine for OEM device makers, rather than directly selling scanners to hospitals. OCT uses reflected light to construct high-resolution cross-sectional images.

AstraNu says its integrated photonics module is more than 10 times smaller than conventional swept-source systems and targets significantly lower system cost. Its first commercial focus is ophthalmology; ENT, urology and oncology integrations are exploratory. Its November 17, 2026 company-issued release confirms a $3.5M Seed led by Celesta Capital with a co-investment from the New Jersey Innovation Evergreen Fund through NJEDA.

Separate January or prior Celesta seed amounts are not disclosed. MobiHealthNews interviewed AstraNu's president, who said customer modules remain in joint development/testing and the team hopes for volume sales around mid-to-late 2027. This is not yet evidence of regulatory clearance, clinical outcomes, mass manufacturing, or booked revenue. Website names founders Michael Eggleston and Bibek Samanta; commercial lead Kevin Blalock.

Why AstraNu is interesting

$3.5M Seed funding supports partner validation and manufacturing preparation. The chip-scale imaging engine is not yet a widely shipped or independently clinically validated finished medical device.

Product & use cases

OEM adoption illustration (not hands-on testing): manufacturer identifies ophthalmic or ENT imaging requirements; asks AstraNu for optical-module specs and sample device; integrates laser, optics, signal processing and software into a larger instrument; validates imaging resolution, stability and thermal/mechanical reliability against existing OCT platform; performs safety/medical-device regulatory and clinical validation applicable to finished product; scales manufacturing only after acceptance. Manufacturer remains responsible for final device integration and clearance. Module price and guaranteed performance are not publicly disclosed.

  • Integrate swept-source OCT into portable ophthalmology instruments where system size currently limits use.
  • Explore portable ear, nose and throat imaging; earlier technology has been demonstrated in middle-ear imaging.
  • Assess lower-footprint imaging modules for new OEM product designs, subject to device qualification.

Key facts

  • $3.5M Seed led by Celesta Capital with New Jersey Innovation Evergreen Fund participation, announced November 17, 2026.
  • Nokia Bell Labs spinout founded May 2025; chip-scale swept-source OCT is currently in partner validation.
  • Volume module sales targeted for mid-to-late 2027, not established 2026 sales.

Funding history (newest first)

Seed

2026-11-17 $3.5M

Source: Read source · prnewswire.com

Competitive landscape

Edge: Company claims integrated photonics reduce physical footprint and bill of materials while retaining swept-source performance, but independently audited system-level cost, reliability and image quality remain to be established.

Manufacturing yield, module optical performance across temperature, application integration, medical-device safety approvals, cost at scale, service/support economics and OEM customer acceptance remain open diligence points.

  • Conventional swept-source OCT component suppliers incumbent

    Larger mature imaging engines with existing OEM integrations; cost/performance require verified comparisons.

  • Spectral-domain OCT solutions alternative

    Established imaging technology with different scan-speed, depth and cost trade-offs.

  • Handheld ultrasound adjacent

    Different imaging physics and clinical indications; cannot substitute for all OCT needs.

Market / IPO context

Editorial / static context — not a live quote.

FAQs about AstraNu

Practical answers founders, operators, and investors typically search for.

AstraNu currently markets a core imaging engine for device manufacturers and development partners, not a broadly available approved finished clinical scanner.
The size comparison is a company statement about its module. Public third-party product-level clinical validation and OEM qualification data have not been established.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.